A new way to treat cancer.
We develop novel cancer therapeutics that effectively kill both dividing and non-dividing cancer cells, improving treatment response and preventing cancer recurrence.
Vision to deliver a true clinical value.
Complete response
By targeting both dividing and non-dividing (dormant) cancer cells we will eliminate residual cancer after therapy .
New Complementary Mechanisms
Our therapies have a new mechanism of action and have a complementary effect with existing therapies.
No more recurrence
Our treatment is designed to destroy residual disease, treating cancer patients in remission to decrease the risk of deadly recurrence.
20 million
New cancer cases annually worldwide
50%
Estimated risk of disease progression and mortality
“We want to give cancer survivors the confidence that their cancer won’t return, and to bring them and their families peace of mind.”
-Dr. Natasha Shtraizent, PhD, Co-founder and CEO of Frezent
Who we are
We are a multidisciplinary team of founders with deep scientific expertise, supported by an advisory board of proven leaders across biotech, business, and oncology therapeutics.
Our Collaborators
We partner with leading hospitals and work with key opinion leaders in oncology.
Frezent is supported by SOSV, New York Ventures and NSF-SBIR grant.
Our Ecosystem
Frezent is an SOSV IndieBio NY portfolio company, and ASRC EDC CAT member. We are part of the growing New York Biotech ecosystem, building on the strong existing and new connections to further our journey from discovery to clinic.
Join us
Reach out for partnerships, investment opportunities, or general inquiries.